L-type Calcium Channel Protein

L-type Calcium Channel Protein

Introduction

<table class="infobox infobox-protein">
<tr>
<th class="infobox-header" colspan="2">L-type Calcium Channel Protein</th>
</tr>
<tr>
<td class="label">L-type Calcium Channel</td>
<td>L-type Calcium Channel Protein</td>
</tr>
<tr>
<td class="label">Feature</td>
<td>Description</td>
</tr>
<tr>
<td class="label">Transmembrane segments</td>
<td>24 segments (6 per domain)</td>
</tr>
<tr>
<td class="label">Selectivity filter</td>
<td>EEEE motif (positions 1394-1397)</td>
</tr>
<tr>
<td class="label">Voltage sensor</td>
<td>Positively charged S4 segments</td>
</tr>
<tr>
<td class="label">C-terminal tail</td>
<td>Multiple regulatory domains (CaM, CaMKII)</td>
</tr>
<tr>
<td class="label">Molecular weight</td>
<td>~250 kDa for α1 subunit</td>
</tr>
<tr>
<td class="label">Approach</td>
<td>Status</td>
</tr>
<tr>
<td class="label">Nifedipine</td>
<td>Clinical trial</td>
</tr>
<tr>
<td class="label">Isradipine</td>
<td>Research</td>
</tr>
<tr>
<td class="label">Cav1.3-selective</td>
<td>Preclinical</td>
</tr>
<tr>
<td class="label">Allosteric modulators</td>
<td>Research</td>
</tr>
<tr>
<td class="label">Drug</td>
<td>Class</td>
</tr>
<tr>
<td class="label">Nifedipine</td>
<td>Dihydropyridine</td>
</tr>
<tr>
<td class="label">Amlodipine</td>
<td>Dihydropyridine</td>
</tr>
<tr>
<td class="label">**Nicardip

L-type Calcium Channel Protein

Introduction

<table class="infobox infobox-protein">
<tr>
<th class="infobox-header" colspan="2">L-type Calcium Channel Protein</th>
</tr>
<tr>
<td class="label">L-type Calcium Channel</td>
<td>L-type Calcium Channel Protein</td>
</tr>
<tr>
<td class="label">Feature</td>
<td>Description</td>
</tr>
<tr>
<td class="label">Transmembrane segments</td>
<td>24 segments (6 per domain)</td>
</tr>
<tr>
<td class="label">Selectivity filter</td>
<td>EEEE motif (positions 1394-1397)</td>
</tr>
<tr>
<td class="label">Voltage sensor</td>
<td>Positively charged S4 segments</td>
</tr>
<tr>
<td class="label">C-terminal tail</td>
<td>Multiple regulatory domains (CaM, CaMKII)</td>
</tr>
<tr>
<td class="label">Molecular weight</td>
<td>~250 kDa for α1 subunit</td>
</tr>
<tr>
<td class="label">Approach</td>
<td>Status</td>
</tr>
<tr>
<td class="label">Nifedipine</td>
<td>Clinical trial</td>
</tr>
<tr>
<td class="label">Isradipine</td>
<td>Research</td>
</tr>
<tr>
<td class="label">Cav1.3-selective</td>
<td>Preclinical</td>
</tr>
<tr>
<td class="label">Allosteric modulators</td>
<td>Research</td>
</tr>
<tr>
<td class="label">Drug</td>
<td>Class</td>
</tr>
<tr>
<td class="label">Nifedipine</td>
<td>Dihydropyridine</td>
</tr>
<tr>
<td class="label">Amlodipine</td>
<td>Dihydropyridine</td>
</tr>
<tr>
<td class="label">Nicardipine</td>
<td>Dihydropyridine</td>
</tr>
<tr>
<td class="label">Verapamil</td>
<td>Phenylalkylamine</td>
</tr>
<tr>
<td class="label">Diltiazem</td>
<td>Benzothiazepine</td>
</tr>
<tr>
<td class="label">Associated Diseases</td>
<td><a href="/wiki/als" style="color:#ef9a9a">ALS</a>, <a href="/wiki/als" style="color:#ef9a9a">Als</a>, <a href="/wiki/alzheimer" style="color:#ef9a9a">Alzheimer</a>, <a href="/wiki/anxiety" style="color:#ef9a9a">Anxiety</a>, <a href="/wiki/cancer" style="color:#ef9a9a">Cancer</a></td>
</tr>
<tr>
<td class="label">KG Connections</td>
<td><a href="/atlas" style="color:#4fc3f7">171 edges</a></td>
</tr>
</table>

L-type calcium channels (LTCCs) are voltage-gated calcium channels that mediate calcium influx in response to membrane depolarization, playing critical roles in neuronal signaling, gene expression, synaptic plasticity, and cellular survival. The Cav1.2 channel, encoded by the CACNA1C gene, is the predominant L-type calcium channel in the brain and is central to the calcium hypothesis of neurodegenerative diseases[@berridge2021].

Cav1.2 channels are among the most extensively studied ion channels in the context of Alzheimer's disease (AD) and Parkinson's disease (PD) due to their central role in calcium dysregulation—a hallmark feature of neurodegeneration[@stanika2019].

Overview

L-type Calcium Channel Protein (Cav1.2) is a 2,373 amino acid, 248.6 kDa voltage-gated calcium channel localized to the cell membrane. It belongs to the Cav1 (L-type) channel family and is composed of a pore-forming α1C subunit (CACNA1C) along with auxiliary β and α2δ subunits[@zhao2020].

Dysregulation of Cav1.2 function contributes to the pathogenesis of Alzheimer's disease, Parkinson's disease, and related neurodegenerative disorders through effects on synaptic plasticity, calcium homeostasis, mitochondrial function, and cellular stress response. Cav1.2 is a major therapeutic target for neuroprotection in neurodegeneration[@zamponi2015].

Structure

Channel Architecture

Cav1.2 is a heteromultimeric complex consisting of:

• Four homologous domains (I-IV), each with 6 transmembrane segments
• Voltage sensor in segment S4
• Selectivity filter with the signature EEEE motif
• C-terminal domain with multiple regulatory sites

• Modulates channel trafficking and gating
• Tissue-specific expression patterns

• Facilitates channel insertion into the membrane
• Alters gating properties

• Tissue-specific auxiliary component

Key Structural Features

Post-translational Modifications

• Phosphorylation by PKA, PKC, CaMKII
• Glycosylation of extracellular domains
• Palmitoylation of C-terminal regions
• Ubiquitination for degradation[@simms2014]

Normal Function

Calcium Influx

Cav1.2 channels open in response to membrane depolarization, allowing Ca2+ influx:

• Activation voltage: -40 to -30 mV (relatively positive)
• Current type: Long-lasting (L-type), slow inactivation
• Conductance: High-voltage activated (HVA)
• Ion selectivity: High preference for Ca2+ over Na+

Key Physiological Roles

Synaptic Plasticity

• Dendritic calcium influx: Triggers Ca2+-dependent signaling cascades
• Gene expression: Activates CREB-mediated transcription
• [Long-term potentiation](/mechanisms/long-term-potentiation) (LTP): Involved in some forms of synaptic strengthening
• Long-term depression (LTD): Participates in synaptic weakening

Neuronal Excitability

• Dendritic spikes: Contributes to back-propagating action potentials
• Calcium electrogenesis: Generates dendritic Ca2+ spikes
• Integration: Modulates synaptic integration in dendrites

Gene Regulation

• Ca2+-dependent transcription: Activates calcineurin, CaMKIV, CREB
• Activity-dependent plasticity: Links neuronal activity to gene expression
• Homeostatic responses: Adjusts neuronal properties to activity levels

Other Tissues

• Cardiac muscle: Primary calcium entry pathway for contraction
• Smooth muscle: Vascular tone regulation
• Endocrine cells: Hormone secretion
• Auditory system (Cav1.3): Cochlear function[@ghosh1995]

Role in Alzheimer's Disease

Calcium Dysregulation Hypothesis

The "calcium hypothesis" of AD proposes that dysregulated calcium signaling is a central mechanism in disease pathogenesis[@berridge2021]. Cav1.2 channels contribute to this through multiple mechanisms:

Amyloid-β Effects

• Direct interaction: [Aβ](/proteins/amyloid-beta) peptides can modulate channel function
• Membrane disruption: Aβ alters lipid environment affecting channels
• Increased influx: Enhanced Ca2+ entry through affected [neurons](/entities/neurons)
• Synaptic dysfunction: Impaired plasticity due to Ca2+ dysregulation

Excitotoxicity

• [NMDA receptor](/entities/nmda-receptor) cross-talk: L-type channels compensate for NMDAR activity
• Excessive influx: Pathological Ca2+ overload
• Downstream activation: Calpain, caspase activation
• Mitochondrial dysfunction: Ca2+ overload of mitochondria

Tau Pathology

• Ca2+ dysregulation: [Tau](/proteins/tau) pathology affects channel function
• Homeostatic disruption: Loss of tau-mediated buffering
• Dendritic spine loss: Ca2+-dependent spine elimination

Therapeutic Implications

Clinical trials of dihydropyridine L-type blockers (e.g., nimodipine, nifedipine) have shown mixed results, with ongoing research into more targeted approaches[@anekonda2015].

Role in Parkinson's Disease

Selective Vulnerability of Dopaminergic Neurons

Midbrain dopaminergic neurons, particularly those in the substantia nigra pars compacta (SNc), show early dysfunction of Cav1.2/Cav1.3 channels:

Cav1.3 Role

• Lower voltage activation: Cav1.3 activates at more negative potentials
• Pacemaker activity: Drives autonomous firing of SNc neurons
• Calcium burden: Continuous activity leads to high Ca2+ influx
• Mitochondrial stress: High energy demands for Ca2+ handling

Mechanisms of Vulnerability

Therapeutic Targeting

Isradipine, a Cav1.2/Cav1.3 blocker, has been investigated in PD clinical trials:

• Rationale: Reduce Ca2+ burden in dopaminergic neurons
• Challenge: Must preserve normal neuronal function
• Outcome: Clinical trials showed modest effects[@surmeier2017]

Role in Other Neurodegenerative Diseases

Amyotrophic Lateral Sclerosis (ALS)

• Motor neuron hyperexcitability: Altered L-type channel function
• Excitotoxicity: Enhanced Ca2+ entry
• Therapeutic potential: Channel modulators under investigation

Timothy Syndrome

• CACNA1C mutations: Cause severe multisystem disorder
• Neurological features: Autism, intellectual disability, seizures
• Modeling: iPSC-derived neurons show altered Ca2+ dynamics

Psychiatric Disorders

• Bipolar disorder: CACNA1C is a genome-wide significant risk gene
• Schizophrenia: Some association with CACNA1C variants
• Mechanism: Altered neuronal excitability and plasticity[@bigos2018]

Therapeutic Targeting

Approved Drugs

Investigational Approaches

Challenges

• [Blood-brain barrier](/entities/blood-brain-barrier): Many drugs have limited CNS penetration
• Cardiac effects: L-type channels crucial for heart function
• Narrow therapeutic window: Balancing efficacy and side effects
• Channel compensatory mechanisms[@dolphin2023]

Key Publications

See Also

• [CACNA1C Gene](/genes/cacna1c)
• [CACNA1D Gene](/genes/cacna1d)
• [Voltage-Gated Calcium Channels](/entities/calcium-channels)
• [Calcium Signaling Pathway](/mechanisms/calcium-signaling-pathway)
• [Excitotoxicity Pathway](/mechanisms/excitotoxicity-pathway)
• [Synaptic Dysfunction Pathway](/mechanisms/synaptic-dysfunction-pathway)
• [Dopaminergic Neurons](/cell-types/dopaminergic-neurons)
• [Alzheimer's Disease](/diseases/alzheimers-disease)
• [Parkinson's Disease](/diseases/parkinsons-disease)

External Links

• [UniProt Q13936 (Cav1.2)](https://www.uniprot.org/uniprot/Q13936)
• [NCBI Gene: CACNA1C](https://www.ncbi.nlm.nih.gov/gene/775)
• [IUPHAR: L-type Calcium Channels](https://www.guidetopharmacology.org/GRID/FamilyIntroduction?familiar=&topfamily=Voltage-gated%20calcium%20channels&subfamily=L-type%20calcium%20channels)
• [PDB: Cav1.2 Structure](https://www.rcsb.org/structure/6JP5)

Background

The study of L Type Calcium Channel Protein has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.

Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.

References